Tyra Bioscience (TYRA) Stock Statistics & Valuation Metrics

Tyra Bioscience has a market cap or net worth of $1.90B. The enterprise value is $1.65B.

Tyra Bioscience has 59,470,383 shares outstanding. The number of shares has decreased by -2.65% in one year.

Tyra Bioscience’s return on equity (ROE) is -0.46 and return on invested capital (ROIC) is -50.10%.

The current PE Ratio of Tyra Bioscience is ―. Tyra Bioscience’s PEG ratio is -0.40.

In the last 12 months, Tyra Bioscience had revenue of 0.00 and earned -119.95M in profits. Earnings per share was -2.01.

In the last 12 months, operating cash flow was -102.25M and capital expenditures -215.00K, giving a free cash flow of -102.47M billion.

Tyra Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Tyra Bioscience upcoming earnings date is Aug 6, 2026, After Close (Confirmed).

Tyra Bioscience as a current ratio of 14.67, with Debt / Equity ratio of 1.47%

In the past 12 months, Tyra Bioscience has paid 0.00 in taxes.

Tyra Bioscience EV to EBITDA ratio is -12.52, with an EV/FCF ratio of -15.69.

Tyra Bioscience has $383.47M in cash and marketable securities with $5.70M in debt, giving a net cash position of $377.77M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Tyra Bioscience is $50.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy